Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 5:48 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 10,867 matching trials from the live ClinicalTrials.gov search.

Filters: Nashville, Tennessee Clear all

Conditions: Locally Advanced (Unresectable) or Metastatic Solid Tumors
Interventions: NEOK001, NEOK001 RDE; Drug
Lead sponsor: NEOK Bio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 9
States / cities: New York, New York • Nashville, Tennessee • Austin, Texas + 4 more

Conditions: Masseter Muscle Prominence
Interventions: BOTOX, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 207 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 20
States / cities: Los Angeles, California • Newport Beach, California • Vista, California + 14 more

Conditions: Advanced Colorectal Cancer, Metastatic Colorectal Cancer
Interventions: MRTX849, Cetuximab, mFOLFOX6 Regimen, FOLFIRI Regimen; Drug · Biological
Lead sponsor: Mirati Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 461 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 185
States / cities: Alabaster, Alabama • Bessemer, Alabama • Birmingham, Alabama + 122 more

Conditions: Actinic Keratoses, Skin Neoplasms
Interventions: Aminolevulinic Acid, Vehicle; Drug · Other
Lead sponsor: DUSA Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 7
States / cities: Irvine, California • San Francisco, California • Miami, Florida + 4 more

Conditions: Migraine
Interventions: AXS-07 (MoSEIC meloxicam and rizatriptan), Placebo; Drug
Lead sponsor: Axsome Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 41
States / cities: Birmingham, Alabama • Mobile, Alabama • Colton, California + 37 more

Conditions: TP53 Y220C Mutation, Advanced Solid Tumors
Interventions: metformin hydrochloride 500 mg tablet, rosuvastatin 10 mg tablet, repaglinide 0.5 mg tablet, midazolam hydrochloride syrup, rezatapopt; Drug
Lead sponsor: PMV Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 5
States / cities: Denver, Colorado • Orlando, Florida • Nashville, Tennessee + 2 more

Conditions: Chronic Hepatitis C
Interventions: Nitazoxanide, Placebo, Peginterferon alfa-2a, Ribavirin; Drug · Biological
Lead sponsor: Romark Laboratories L.C.; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 10
States / cities: Palo Alto, California • Stanford, California • New Haven, Connecticut + 7 more

Conditions: Lymphoma
Interventions: autologous immunoglobulin idiotype-KLH conjugate vaccine, keyhole limpet hemocyanin, sargramostim, cyclophosphamide, prednisone, vincristine sulfate; Biological · Drug
Lead sponsor: Genitope Corporation; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 21
States / cities: Dublin, California • Greenbrae, California • Los Angeles, California + 16 more

Conditions: Advanced Solid Tumors, Metastatic Colon Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Rectal Cancer
Interventions: Fruquintinib (HMPL-013); Drug
Lead sponsor: Hutchison Medipharma Limited; Industry
Eligibility: 18 Years and older
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 9
States / cities: Phoenix, Arizona • San Marcos, California • Santa Rosa, California + 6 more

Conditions: Pseudobulbar Affect (PBA)
Interventions: dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg, dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg, Placebo; Drug
Lead sponsor: Avanir Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 326 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 45
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Anaheim, California + 39 more

Conditions: Lymphoma, Non-Hodgkin, Chronic Lymphocytic Leukemia
Interventions: IMGN529; Drug
Lead sponsor: ImmunoGen, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 6
States / cities: Boston, Massachusetts • New York, New York • Columbus, Ohio + 3 more

Conditions: Systemic Lupus Erythematosus
Interventions: Low Dietary Sodium, High Dietary Sodium; Dietary Supplement
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Migraine With Aura
Interventions: Active Transcranial Magnetic Stimulation (TMS) Device, Sham TMS Device; Device
Lead sponsor: Neuralieve; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 201 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 14
States / cities: San Francisco, California • Denver, Colorado • Chicago, Illinois + 11 more

Conditions: Advanced Solid Tumors
Interventions: ASP1002, Bevacizumab, Oxaliplatin, Leucovorin, Fluorouracil, Irinotecan, Trifluridine-Tipiracil, Pembrolizumab, Pemetrexed, Carboplatin, Ramucirumab, Docetaxel; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 798 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 15
States / cities: New Haven, Connecticut • Plainville, Connecticut • Gainesville, Florida + 11 more

Conditions: Diabetes
Interventions: Active Control, int arm 1, int arm 3; Behavioral
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: HIV Infections, Chickenpox
Interventions: Varicella Virus Vaccine (Live); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 2 Years to 18 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2004
U.S. locations: 22
States / cities: Long Beach, California • Los Angeles, California • Torrance, California + 13 more

Conditions: Ventricular Tachycardia (VT)
Interventions: Sphere-9 Catheter with the Affera Mapping and Ablation System; Device
Lead sponsor: Medtronic Cardiac Ablation Solutions; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 6
States / cities: Boston, Massachusetts • New York, New York • Cleveland, Ohio + 3 more

Conditions: Lymphoma, Non-Hodgkin's Lymphoma, Hodgkin Disease, Multiple Myeloma, Leukemia, Lymphocytic
Interventions: PCI-24781; Drug
Lead sponsor: Pharmacyclics LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 5
States / cities: Chicago, Illinois • Lafayette, Indiana • Omaha, Nebraska + 1 more

Conditions: Carcinoma, Renal Cell
Interventions: Belzutifan, Everolimus; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 755 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 29
States / cities: Birmingham, Alabama • La Jolla, California • Santa Rosa, California + 23 more

Conditions: Parkinson Disease
Interventions: Frequency change to 60 Hz, Frequency change to 130 Hz; Procedure
Lead sponsor: Vanderbilt University; Other
Eligibility: Not listed
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Alpha 1 Antitrypsin Deficiency, AATD
Interventions: Not listed
Lead sponsor: University of Pittsburgh; Other
Eligibility: 40 Years to 80 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 9
States / cities: Tucson, Arizona • San Francisco, California • Denver, Colorado + 6 more

Conditions: Stroke, Secondary Prevention
Interventions: optional ASA as comedication, placebo to ASA, placebo to optional ASA as comedication, placebo to dabigatran etexilate, ASA 100 mg, dabigatran etexilate; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 150 Years
Enrollment: 5,390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 110
States / cities: Phoenix, Arizona • Beverly Hills, California • El Cajon, California + 94 more

Conditions: Non-small Cell Lung Cancer, Histiocytic Neoplasm, Histiocytosis, BRAF Gene Mutation, BRAF V600E, BRAF V600 Mutation, BRAF Mutation-Related Tumors, BRAF, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Cancer, Recurrent Lung Cancer, Recurrent Lung Non-Small Cell Carcinoma, NSCLC, Solid Tumor, Solid Carcinoma, KRAS G12D, KRAS G12V, KRAS Mutation-Related Tumors, NRAS Gene Mutation, Thyroid Cancer, Thyroid Carcinoma, Colorectal Cancer, Colorectal Carcinoma, Recurrent Histiocytic and Dendritic Cell Neoplasm, Brain Metastases, Recurrent NSCLC, KRAS G13C, Acquired Resistance to KRAS G12C Inhibitor, KRAS G12A, KRAS G12F, KRAS G12R, KRAS G13D
Interventions: S241656, FOLFOX6/FOLFOX7, FOLFIRI, Cetuximab, Panitumumab, Gemcitabine, Nab-paclitaxel; Drug
Lead sponsor: Institut de Recherches Internationales Servier; Other
Eligibility: 18 Years and older
Enrollment: 554 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 21
States / cities: Gilbert, Arizona • Los Angeles, California • San Francisco, California + 15 more

Conditions: Lung Diseases, Hypertension, Pulmonary
Interventions: Not listed
Lead sponsor: Vanderbilt University; Other
Eligibility: Up to 100 Years
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: Nashville, Tennessee

Search by objective public record fields.

A Study of NEOK001, a B7-H3 and ROR1 Targeting Bispecific ADC in Participants With Select Solid Tumors

A Study to Assess BOTOX Injections for the Change of Masseter Muscle Prominence in Adult Participants

Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)

ALA-PDT Versus Vehicle PDT for Treatment of AK and Reduction of New NMSC in Solid Organ Transplant Recipients

Initiating Early Control of Migraine Pain and Associated Symptoms

A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.

Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin for the Treatment of Hepatitis C

Combination Chemotherapy Followed By Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Non-Hodgkin's Lymphoma

A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast Cancers

Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS

IMGN529 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia

Tissue Sodium in Autoimmune Disease

Efficacy and Safety of TMS for the Preemptive Treatment of Migraine With Aura

A Study of ASP1002 in Adults for Treatment of Solid Tumors

Addressing The Role of Nutrition Education & Health Literacy in Diabetes Care

Use of a Varicella-Zoster Virus (VZV) Vaccine to Prevent Shingles in HIV-Infected Children Who Have Already Had Chickenpox

Safety and Performance Assessment of the Sphere-9™ Catheter and Affera™ Ablation System for the Treatment of Ventricular Tachycardia (Sphere-9 VT EFS)

A Safety and Tolerability Study of PCI-24781 in Subjects With Cancer

A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)

Deep Brain Stimulation (DBS) Frequency Effects on Gait in Parkinson's Disease(PD)

Genomic Research in Alpha-1 Antitrypsin Deficiency

Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Genetic and Environmental Characteristics of Primary Pulmonary Hypertension